All News
☝️Treatment is the 3rd reason why we need to order a BL HRCT in pts with ILD; "We can't treat SSc-ILD if we are not able to detect SSc-ILD" - Dr. Elana Bernstein
#ACR @RheumNow #rheumatology https://t.co/ooZVSbt3Xf
sheila RHEUMarampa ( View Tweet)
Ab1672 #ACR22 SSc on Women's Health
100 pts - 75% lSSc
59% sexuality aff by SSc (vag dryness 67%, dig ulcers 37%, GI 37%, dyspnea 20%)
48 pts dx during repro ys - 73% never discuss contraception, 30% didn't reach family plan
22 pt - 43 pregn, 33 birth: C-sxn, low bth wt
@Rheumnow https://t.co/JRkyCVEXLB
Eric Dein ericdeinmd ( View Tweet)
Mihai et al. Immunosuppressive treatment in SSc assoc lower GI symptom score. @RheumNow #ACR22 Abstr#2174 https://t.co/Y1gyRe8ron https://t.co/tz9cIESzqo
Richard Conway RichardPAConway ( View Tweet)
Quinlivan et al. GORD in SSc. Common - 94%. GORD treatment assoc improved survival HR 0.58. No assoc with ILD development/severity/progression but GORD treatment assoc improved survival in ILD HR 0.5. If PPI+H2 HR 0.33 . @RheumNow #ACR22 Abstr#2159 https://t.co/zk718ziFGJ https://t.co/WctfOr9qyf
Richard Conway RichardPAConway ( View Tweet)
DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and access remain. Abs 1541 #ACR22 @RheumNow https://t.co/KJgtcG5ah8 https://t.co/NsK7b8fQFt
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22
@jhrheumatology @JHRheumFellows
https://t.co/aSRHiJoIkE
Eric Dein ericdeinmd ( View Tweet)
Goldman et al. RTX, TCZ in SSc ILD. 129 patients, 87 RTX, 32 TCZ, 10 both. Median changes in %FVC and %DLCO pre-and post-treatment were +0.35% and -0.8% for rituximab and -0.9% and +0.2% for tocilizumab. Majority stable/improved @RheumNow #ACR22 Abstr#1520 https://t.co/ydY5FGEYnQ https://t.co/O9QD7nkjdZ
Richard Conway RichardPAConway ( View Tweet)
Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of early SSc! @RheumNow #ACR22 Abstr#1536 https://t.co/nKiY2xFxfk https://t.co/W7SDm6QFpQ
Richard Conway RichardPAConway ( View Tweet)
Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and higher risk of developing multimorbidity over time @RheumNow #ACR22 Abstr#1190 https://t.co/VopFI6U5G5 https://t.co/hKKPC7v8EN
Richard Conway RichardPAConway ( View Tweet)
Herrán et al. Anti-vinculin abs in SSc. Single centre. Seen in 25%. Slow gastric transit (37% vs 21%). More LcSSc (OR 5), more thyroid disease (OR 3.2), less lung (OR 0.19). @RheumNow #ACR22 Abstr#1068 https://t.co/kPVgWPUl00 https://t.co/kmTERf78Ae
Richard Conway RichardPAConway ( View Tweet)
Ramahi @sclerodermaUM et al Risk factors for ILD decline in SSc. Anti-Topoisomerase I only identified factor in multivariable model. @RheumNow #ACR22 Abstr#1524 https://t.co/lc2BPjgqiC https://t.co/qx3M6dfd3w
Richard Conway RichardPAConway ( View Tweet)
Yen et al. Taiwanese study of risk of MACE in SSc. No difference in MACE IRR 1.15 (95%CI 0.87–1.52) or stroke IRR 0.89 (95%CI 0.61-1.29), increase in MI IRR 1.76 (95%CI 1.08-2.86) @RheumNow #ACR22 Abstr#1191 https://t.co/3BiTLafGmk https://t.co/IManEvAh47
Richard Conway RichardPAConway ( View Tweet)
There's a lot of Scleroderma-like fibrosing skin disorders!
#ACR22 @RheumNow #RheumTwitter @rheumarhyme https://t.co/W1AEtfeKZc
sheila RHEUMarampa ( View Tweet)
Scleredema has an indolent course
Affected skin is doughy
Has 3 clinical subgrps:
💠classic adultorum - self-limited, +visceral involvement
💠blood dyscrasia
💠diabetes - visceral involvement is rare
#ACR22 @Rheumnow @rheumarhyme https://t.co/ZlQmCc1WYa
sheila RHEUMarampa ( View Tweet)
#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm
Richard Conway RichardPAConway ( View Tweet)
Dr. Wigley describes the edematous phase of early #scleroderma:
☝️ Friction rubs are a sign of active disease and assoc. with poor outcomes
#ACR22 @RheumNow @rheumarhyme https://t.co/ooXYp1wXzu
sheila RHEUMarampa ( View Tweet)
☝️Remember: Not all skin thickening is SSc!
🔸Lipodermatosclerosis is a differential. Has an inverted champagne bottle appearance - caused by venous stasis and venous HTN
#ACR22 @RheumNow #Scleroderma #RheumTwitter https://t.co/joWWn6BnVC
sheila RHEUMarampa ( View Tweet)
Add GPA to the list of causes of dacryoadenitis (inflammation of the lacrimal gland, main or accessory). Differential diagnoses of dacryoadenitis:
● Sjogren's
● Sarcoidosis
● IgG4 RD
● AL Amyloidosis
● GPA
John Stone, Secrets and Pearls #ACR22 @RheumNow https://t.co/dvXbkpfcAq
Dr. Antoni Chan synovialjoints ( View Tweet)
Khanna @sclerodermaUM. SLS-III MMF+Pirfenidone vs MMF alone in SSc-ILD. Underpowered due to COVID (51 vs 150). No difference FVC 18 months ?more rapid improvement in combo. Better HRCT, PROs in combination. Need another study! @RheumNow #ACR22 Abstr#0520 https://t.co/K2Ne6PSHkS https://t.co/P6A7OJpzCf
Richard Conway RichardPAConway ( View Tweet)
